FDA RPD Designation Granted for RC220 Bisantrene
Released 17 Jun 24
Latest announcements
Announcement summary
FDA RPD Designation Granted for RC220 Bisantrene
Ask a question
Your question will be sent privately to Race Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Race Oncology a question about this announcement.